/clinical/,/clinical/pted/,/clinical/pted/hffy/,/clinical/pted/hffy/cancer/,

/clinical/pted/hffy/cancer/6001.hffy

201707194

page

100

UWHC,UWMF,

Clinical Hub,Patient Education,Health and Nutrition Facts For You,Cancer, BMT, Hematology

Bevacizumab (Avastin) for the Treatment of Cancer (6001)

Bevacizumab (Avastin) for the Treatment of Cancer (6001) - Clinical Hub, Patient Education, Health and Nutrition Facts For You, Cancer, BMT, Hematology

6001



Bevacizumab (Avastin)
For the Treatment of Cancer

Description

This is a monoclonal antibody which is a
protein that inhibits (slows) the growth of
new blood vessels. Tumors need to build
blood vessels to grow.

How It Is given

The first IV (intravenous) dose is given over
90 minutes. The second dose is given over
60 minutes. The rest of the doses are given
over 30 minutes. Doses are given every 2
weeks. Blood and sometimes urine will
need to be checked on a routine basis.

Common side effects

• Increased blood pressure during and/or
after treatment
• Headache
• Decreased appetite related to dry mouth
and/or nausea
• Changes in taste
• Constipation or diarrhea
• Decreased ability for wounds to heal
• Nose bleeds

Uncommon side effects

• Kidney changes --Your doctor will
check lab tests and possibly a urinalysis.
• Allergic reaction.
• Abdominal pain

Call Your Health Care Provider if You
Develop

• Coughing blood, nosebleeds which you
cannot stop, blood in stool, urine or
vaginally.
• Abdominal pain
• A change in your blood pressure.
• Headache unrelieved by acetaminophen
(Tylenol®)
• Pain, tenderness, and/or swelling in your
lower legs
• New or worsening shortness of breath
• Symptoms of an allergic reaction such
as:
o Rash
o Flushing
o Itching or hives
o New or increased problems breathing
or wheezing

Special Concerns

▪ This drug will slow wound healing. You
should avoid any surgery during
treatment and for 28 days once treatment
is completed. This includes placement
of an Infusaport.
▪ You must take proper precautions to
prevent pregnancy for yourself or any
sexual partners during treatment and for
a period of time once treatment is
completed.








Adapted, with permission, from the Genentech
package insert.



Your health care team may have given you this
information as part of your care. If so, please use it
and call if you have any questions. If this information
was not given to you as part of your care, please
check with your doctor. This is not medical advice.
This is not to be used for diagnosis or treatment of
any medical condition. Because each person’s health
needs are different, you should talk with your doctor
or others on your health care team when using this
information. If you have an emergency, please call
911. Copyright © 7/2017. University of Wisconsin
Hospitals and Clinics Authority. All rights reserved.
Produced by the Department of Nursing. HF#6001